Capricor Therapeutics (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.
CAPR’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. The HOPE-Duchenne trial was funded in part by the California Institute for Regenerative Medicine.
CAPR is one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
The company was founded in 2005 and is headquartered in Beverly Hills, California.
February 29, 2024
RegMed Investors’ (RMi) pre-open: a hot inflation report could trigger significant selling as earnings keep on coming
February 28, 2024
RegMed Investors (RMi) Closing Bell: run from sector highs to cash as a portfolio value preservation strategy
October 27, 2023
RegMed Investors’ (RMi) pre-open: sentiment is not in investors hands
October 26, 2023
RegMed Investors (RMi) Closing Bell: market dives, sector thrives
March 29, 2022
RegMed Investors’ (RMi) pre-open: the cell and gene therapy sector is caught in a cycle of unpredictability
October 21, 2021
RegMed Investors’ (RMi) closing bell: expectation or causation
October 21, 2021
RegMed Investors’ (RMi) pre-open: markets and share pricing risks deflate sentiment = uncertainty
October 6, 2021
RegMed Investors’ (RMi) closing bell: stem, cell and gene therapy sector stumbles
October 5, 2021
RegMed Investors’ (RMi) closing bell: a barely upside turnaround
35 companies, 1 interpreter!
Insight, foresight and recommendation
Capricor (CAPR) --January started out at $1.57 with a high of $1.70 beginning February at $1.83. a high of $2.00 on 2/15 dropping to $1.85 on 2/16 … CAPR desperately NEEDS to re-finance, be ready for depreciation and dilution -
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors